Grabar Law Office is investigating claims on behalf of shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company that engages in the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy and other diseases with unmet medical needs in the United States.

As alleged in a recently filed federal securities fraud class action, Capricor and its Chief Executive Officer, provided investors with overwhelmingly positive statements to investors as to material information concerning Capricor’s lead cell therapy candidate drug deramiocel – used for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy. These statements included, among other things, Capricor’s ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration.

The Complaint alleges that these overwhelmingly positive statements were made to investors while, at the same time, Capricor and its CEO disseminated false and misleading statements and/or concealed material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel, causing Plaintiff and other shareholders to purchase Capricor’s securities at artificially inflated prices

WHAT YOU CAN DO NOW: If you purchased Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares prior to October 9, 2024, and still hold shares today, you are encouraged to contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.  You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.  If, alternatively, you purchased your shares between
October 9, 2024, and July 10, 2025, you can participate in the class action.